Acadia Pharmaceuticals (ACAD) Receivables - Other (2013 - 2026)

Acadia Pharmaceuticals' Receivables - Other history runs 14 years deep, the most recent figure standing at $13.0 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 63.52% year-over-year to $13.0 million; the TTM figure through Mar 2026 stood at $13.0 million (up 63.52% YoY), while the FY2025 annual figure was $26.8 million, up 349.53% from the prior year.
• Receivables - Other for Q1 2026 stood at $13.0 million, down from $26.8 million in the prior quarter.
• The five-year high for Receivables - Other was $26.8 million in Q4 2025, with the low at $403000.0 in Q3 2022.
• The 5-year median for Receivables - Other is $5.4 million (2024), against an average of $7.6 million.
• The sharpest annual moves came in 2022 and 2024: Receivables - Other sank 58.54% in 2022, then jumped 602.54% in 2024.
• Acadia Pharmaceuticals' Receivables - Other stood at $885000.0 in 2022, then jumped by 361.36% to $4.1 million in 2023, then jumped by 45.87% to $6.0 million in 2024, then soared by 349.53% to $26.8 million in 2025, then slumped by 51.32% to $13.0 million in 2026.
• Business Quant data shows ACAD's Receivables - Other at $13.0 million in Q1 2026, $26.8 million in Q4 2025, and $23.6 million in Q3 2025.